Literature DB >> 11147296

Pathologic significance of proliferative activity and oncoprotein expression in astrocytic tumors.

X W Bian1, J Q Shi, F X Liu.   

Abstract

OBJECTIVE: To clarify the clinicopathologic significance of immunohistochemistry for proliferative activity and oncoprotein expression in astrocytic tumors. STUDY
DESIGN: Ninety-seven cases of brain astrocytic tumors with histologic grading and follow-up data were investigated with immunohistochemistry and image analyzer to detect the expression of proliferating cell nuclear antigen (PCNA), silver-binding nucleolar organizer regions (AgNORs) and several oncoproteins.
RESULTS: PCNA was significantly related to AgNORs, grading and prognosis of astrocytomas. The frequency of mutant p53 protein expression was higher in grade 2-4 astrocytomas than in grade 1. Epidermal growth factor (EGF) (37.1%), EGF receptor (83.5%) and p21ras (42.3%) expression levels were related to neither the grade nor prognosis of the tumors. The positive ratios of p53 antibodies were higher in grades 2-4 than in grade 1, and the intensities correlated with PCNA but not with prognosis.
CONCLUSION: Aberrations of c-erbB-2, p21ras, EGF and EGF receptor might be early events in the initiation and progression of astrocytomas, whereas p53 overexpression is involved in all the stages. Immunohistochemical detection had no prognostic value. PCNA could be important to the evaluation of astrocytoma malignancy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11147296

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  6 in total

1.  Increasing of HER2 membranar density in human glioblastoma U251MG cell line established in a new nude mice model.

Authors:  Jean-François Mineo; Anne Bordron; Isabelle Quintin-Roué; Quintin-Roué Isabelle; Claude-Alain Maurage; Virginie Buhé; Buhé Virginie; Séverine Loisel; Loisel Séverine; François Dubois; Serge Blond; Christian Berthou
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

2.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

3.  In vivo research in astrocytoma cell proliferation with 1H-magnetic resonance spectroscopy: correlation with histopathology and immunohistochemistry.

Authors:  Jun Chen; Shu-Lan Huang; Tao Li; Xi-Lan Chen
Journal:  Neuroradiology       Date:  2006-03-22       Impact factor: 2.804

4.  Immunohistochemical markers for prognosis of cerebral glioblastomas.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

5.  c-erbB-2 protein expression in astrocytic tumors of the brain.

Authors:  Joanna Reszeć; Piotr S Bernaczyk; Robert Milewski; Lech Chyczewski; Zenon Mariak
Journal:  Med Sci Monit       Date:  2011-08

6.  Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas.

Authors:  J-F Mineo; A Bordron; I Quintin-Roué; S Loisel; K L Ster; V Buhé; N Lagarde; C Berthou
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.